A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT05320692
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TACE+Camrelizumab+Apatinib mesylate — DRUG
    TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
  • TACE — PROCEDURE
    TACE Alone.

Study Details

A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.

Key Dates

Start date
Aug 9, 2022
Status verified
Dec 2025
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026

Study Design

Enrollment
423 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group
    TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib).
  • Active Comparator: Control group
    TACE Alone.

Primary Outcome Measure

PFS assessed by BIRC [ Time Frame: approximately 5 years ]

Related Studies